Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold® adjuvant against experimental fasciolosis in rats
PBN-AR
Instytucja
Instytut Parazytologii im. Witolda Stefańskiego Polskiej Akademii Nauk
Informacje podstawowe
Główny język publikacji
angielski
Czasopismo
VACCINE (30pkt w roku publikacji)
ISSN
0264-410X
EISSN
Wydawca
ELSEVIER SCI LTD
DOI
URL
Rok publikacji
2017
Numer zeszytu
4
Strony od-do
663-671
Numer tomu
35
Identyfikator DOI
Liczba arkuszy
Autorzy
(liczba autorów: 13)
Pozostali autorzy
+ 11
Słowa kluczowe
angielski
MRLC
angielski
Fasciola hepatica
angielski
Vaccine
Streszczenia
Język
angielski
Treść
Protection against experimental fasciolosis in rats immunized with recombinant myosin regulatory light chain (MRLC) in TiterMax Gold® adjuvant was assessed. The experimental trial consisted of four groups of 15 animals; group 1 was unimmunized and infected, group 2 was immunized with MRLC in adjuvant and infected, group 3 was infected and immunized with adjuvant only and group 4 was unimmunized and uninfected. Immunization with MRLC in TiterMax Gold® adjuvant (group 2) induced a reduction in fluke burdens of 51.0% (p<0.001) when compared with the adjuvant control group, and 61.5% (p<0.001) when compared with the unimmunized infected controls. There was a reduction in fecal egg output in group 2 of 44.8% and 37.3% compared with group 1 and group 3, respectively; although this difference was not statistically significant. Measurement of cytokine levels revealed higher levels of TNF-alpha and IL-2 as well as lower levels of IL-4 in group 2 during the chronic stage of infection (p<0.05), along with higher levels of IFN-gamma during early stages of infection (p<0.05). These results suggest a mixed Th1/Th2 phenotype immune response; however predominance of Th1 cytokines was observed. Levels of anti-MRLC serum IgG in group 2 were significantly higher than controls at the time of euthanasia (p<0.05). This is the first report of immunization with recombinant MRLC in rats, demonstrating that this antigen significantly reduces fluke burdens, increases the Th1 immune response and encourages further studies to improve the vaccine's efficacy.
Cechy publikacji
Original paper
Inne
System-identifier
PX-599ae6afd5de964fa1559838
CrossrefMetadata from Crossref logo
Cytowania
Liczba prac cytujących tę pracę
Brak danych
Referencje
Liczba prac cytowanych przez tę pracę
Brak danych